|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2002, Vol. 100, No. 1, pp. 167-173
IMMUNOBIOLOGY
T-cell responses against chronic lymphocytic leukemia cells:
implications for immunotherapy
Angela M. Krackhardt,
Sabine Harig,
Mathias Witzens,
Ryan Broderick,
Patrick Barrett, and
John G. Gribben
From the Department of Adult Oncology, Dana-Farber
Cancer Institute, Department of Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA.
Chronic lymphocytic leukemia (CLL) cells are ineffective
antigen-presenting cells (APCs) although CD40-activated CLL cells can
stimulate proliferation of autologous and allogeneic T cells. We
examined the antigen-presenting capacity of CD40-activated CLL cells as
well as dendritic cells pulsed with apoptotic bodies of CLL cells to
generate autologous and allogeneic immune responses against CLL cells.
Both APC types were capable of generating T-cell lines that proliferate
specifically in response to unstimulated CLL cells. Whereas cytotoxic
responses against stimulated and unstimulated CLL cells could be
repeatedly generated by allogeneic healthy donors, autologous cytotoxic
immune responses against CD40-activated and native CLL cells were
rarely detected. However, T cells isolated from patients with CLL could
recognize and lyse allogeneic stimulated and unstimulated CLL cells,
demonstrating that cytotoxic T cells from these tumor-bearing patients
are functionally intact.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Gorgun, A. G. Ramsay, T. A. W. Holderried, D. Zahrieh, R. Le Dieu, F. Liu, J. Quackenbush, C. M. Croce, and J. G. Gribben
E{micro}-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
PNAS,
April 14, 2009;
106(15):
6250 - 6255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Galletti, C. Canones, P. Morande, M. Borge, P. Oppezzo, J. Geffner, R. Bezares, R. Gamberale, and M. Giordano
Chronic Lymphocytic Leukemia Cells Bind and Present the Erythrocyte Protein Band 3: Possible Role as Initiators of Autoimmune Hemolytic Anemia
J. Immunol.,
September 1, 2008;
181(5):
3674 - 3683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. G. Schuster, D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nossner, et al.
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies
Blood,
October 15, 2007;
110(8):
2931 - 2939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Kater, M. H. J. van Oers, and T. J. Kipps
Cellular immune therapy for chronic lymphocytic leukemia
Blood,
October 15, 2007;
110(8):
2811 - 2818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gary-Gouy, A. Sainz-Perez, J.-B. Marteau, A. Marfaing-Koka, J. Delic, H. Merle-Beral, P. Galanaud, and A. Dalloul
Natural Phosphorylation of CD5 in Chronic Lymphocytic Leukemia B Cells and Analysis of CD5-Regulated Genes in a B Cell Line Suggest a Role for CD5 in Malignant Phenotype
J. Immunol.,
October 1, 2007;
179(7):
4335 - 4344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
Blood,
November 15, 2005;
106(10):
3515 - 3523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hoogendoorn, J. Olde Wolbers, W. M. Smit, M. R. Schaafsma, I. Jedema, R. M.Y. Barge, R. Willemze, and J.H. F. Falkenburg
Primary Allogeneic T-Cell Responses against Mantle Cell Lymphoma Antigen-Presenting Cells for Adoptive Immunotherapy after Stem Cell Transplantation
Clin. Cancer Res.,
July 15, 2005;
11(14):
5310 - 5318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Gricks, D. Zahrieh, A. J. Zauls, G. Gorgun, D. Drandi, K. Mauerer, D. Neuberg, and J. G. Gribben
Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells
Blood,
December 15, 2004;
104(13):
4002 - 4009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben
CD40 activation: potential for specific immunotherapy in B-CLL
Ann. Onc.,
June 1, 2004;
15(6):
853 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Blood,
March 1, 2004;
103(5):
1763 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Grube, K. Rezvani, A. Wiestner, H. Fujiwara, G. Sconocchia, J. J. Melenhorst, N. Hensel, G. E. Marti, L. W. Kwak, W. Wilson, et al.
Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies
Clin. Cancer Res.,
February 1, 2004;
10(3):
1047 - 1056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers
Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia
Blood,
August 1, 2003;
102(3):
1057 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
